Answers are grounded in this paper and cite their sources.
PROs were infrequently used in pediatric cancer registration trials. When PROs were used, PRO data were limited by lack of a clear research objective and corresponding prospective statistical analysis plan. Contemporary PRO symptom libraries, such as the National Cancer Institute's Pediatric PRO-CTCAE, may provide an opportunity to better evaluate the occurrence and impact of symptomatic AEs, from the patient's perspective, in pediatric oncology trials.
No takes yet. Share an insight, caveat, or question.
Murugappan et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: